NNVC
Nanoviricides, Inc.
$1.77
+0.05 (+2.91%)
At close · Jul 16
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management believes that the Company’s cash and cash equivalents balance of approximately $3.2 million, and the Company’s existing resources, including availability under its $3 million line of credit will not be sufficient to fund the Company’s planned operations and expenditures for at least 12 months from the date of the filing of this Form 10-Q. As a result, substantial doubt exists about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$38.10M
Shares
21,647,000
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2025
Net Income
-$9.47M
-14.1%
FY2025
Diluted EPS
-$0.63
+10%
FY2025
Operating Cash Flow
-$8.48M
-34.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $4.58M | $5.55M | $5.44M | $6.39M | $5.78M | $6.11M | $4.7M | $5.92M | $5.91M | $6.57M | $5.03M | $3.66M | $5.13M | $4.29M | $4.27M | $4.16M | $3.37M | — | — | — | — | |
| $3.6M | $4.04M | $3.08M | $2.55M | $2.33M | $2.63M | $3.3M | $2.74M | $3.41M | $3.03M | $3.83M | $3.4M | $3.54M | $2.3M | $1.82M | $2.27M | $1.74M | — | — | — | — | |
| $8271 | $8269 | $8270 | $8270 | $8270 | $8270 | $8270 | $8271 | $8269 | $8269 | — | — | — | — | — | — | — | — | — | — | — | |
| $8.18M | $9.59M | $8.52M | $8.94M | $8.11M | $8.74M | $8M | $8.66M | $9.33M | $9.6M | $8.86M | $7.06M | $8.67M | $6.59M | $6.08M | $6.43M | $4.94M | — | — | — | — | |
| -$8.18M | -$9.59M | -$8.52M | -$8.94M | -$8.11M | -$8.74M | -$8M | -$8.66M | -$9.33M | -$9.6M | -$8.86M | -$7.06M | -$8.67M | -$6.59M | -$6.08M | -$6.43M | -$4.94M | — | — | — | — | |
| — | $149 | $49.81K | $938 | $5123 | $85.41K | $93.67K | $0 | $185.27K | $780.77K | $1.04M | $2.65M | $3.09M | $962.54K | $0 | $0 | — | — | — | — | — | |
| $130.36K | — | — | — | — | — | — | — | — | — | — | $160.86K | $171K | $55.59K | $46.79K | $14.34K | $2980 | — | — | — | — | |
| $84.69K | $124.68K | $221.97K | $354.9K | $6736 | -$78.08K | -$5.45M | $235.24K | $761.71K | -$703.77K | -$1.87M | $4.86M | -$4.93M | -$2.29M | -$125.46K | -$47.71K | $195.74K | — | — | — | — | |
| — | — | — | — | -$8.11M | -$8.82M | -$13.45M | -$8.42M | -$8.56M | -$10.3M | -$10.72M | -$2.2M | -$13.6M | -$8.88M | -$6.21M | -$6.48M | -$4.74M | — | — | — | — | |
| — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | |
| -$8.09M | -$9.47M | -$8.29M | -$8.59M | -$8.11M | -$8.82M | -$13.45M | -$8.42M | -$8.56M | -$10.3M | -$10.72M | -$2.2M | -$13.6M | -$8.88M | -$6.21M | -$6.48M | -$4.74M | -$2.79M | -$2.74M | -$3.12M | -$3.28M | |
| — | — | — | — | — | — | — | — | -$8.56M | -$10.3M | -$10.72M | -$2.2M | -$13.6M | -$8.88M | — | — | — | — | — | — | — | |
| USD/shares | — | -$0.63 | -$0.70 | -$0.74 | -$0.70 | -$0.81 | — | — | -$0.13 | -$0.17 | -$0.19 | -$0.04 | -$0.27 | -$0.19 | — | — | — | — | — | — | — |
| USD/shares | — | -$0.63 | -$0.70 | -$0.74 | -$0.70 | -$0.81 | — | — | -$0.13 | -$0.17 | -$0.19 | -$0.09 | -$0.27 | -$0.19 | — | — | — | — | — | — | — |
| shares | — | 15.12M | 11.87M | 11.63M | 11.53M | 10.9M | 5.62M | 3.59M | 64.92M | 60.1M | 57.67M | 56.55M | 51.23M | 45.89M | 42.76M | 39.77M | 130.5M | — | — | — | — |
| shares | — | 15.12M | 11.87M | 11.63M | 11.53M | 10.9M | 5.62M | 3.59M | 64.92M | 60.1M | 57.67M | 59.22M | 51.23M | 47.61M | 42.76M | 39.77M | 130.5M | — | — | — | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.53×
EV/EBIT
—
Biotechnology median 26.64×
P/E (TTM)
—
Biotechnology median 7.53×